Cargando…
Ipilimumab and radiation therapy for melanoma brain metastases
Ipilimumab, an antibody that enhances T-cell activation, may augment immunogenicity of tumor cells that are injured by radiation therapy. We hypothesized that patients with melanoma brain metastasis treated with both ipilimumab and radiotherapy would have improved overall survival, and that the sequ...
Autores principales: | Silk, Ann W, Bassetti, Michael F, West, Brady T, Tsien, Christina I, Lao, Christopher D |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3892394/ https://www.ncbi.nlm.nih.gov/pubmed/24403263 http://dx.doi.org/10.1002/cam4.140 |
Ejemplares similares
-
Survival of melanoma patients with brain metastases treated with ipilimumab and stereotactic radiosurgery
por: Tazi, Karim, et al.
Publicado: (2015) -
Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases
por: Queirolo, Paola, et al.
Publicado: (2014) -
Focal radiation necrosis of the brain in patients with melanoma brain metastases treated with pembrolizumab
por: Du Four, Stephanie, et al.
Publicado: (2018) -
Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES)
por: Lau, Peter Kar Han, et al.
Publicado: (2021) -
Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
por: Chapman, Paul B, et al.
Publicado: (2021)